New Lymphoma Drug IKS03 to Show Updated Data

Early trial results in advanced B-cell lymphoma will be presented at the December 2026 ASH meeting.

Updated on Nov. 7, 2026 in Cancer

Bold flat-color vector editorial illustration of a single amber glass vial beside a teal antibody-shaped form on a plain background, evoking early drug-development research.
Iksuda Therapeutics will present updated early phase 1 results for its experimental lymphoma drug IKS03 at the American Society of Haematology meeting in New Orleans on December 12 to 15, 2026. AI Illustration. Upload story photo >

Iksuda Therapeutics reported preliminary phase 1 data for IKS03, an experimental antibody drug conjugate, in adults with advanced B-cell non-Hodgkin lymphoma. Updated results are scheduled for presentation at the 68th American Society of Haematology Annual Meeting in New Orleans, December 12 to 15, 2026, for patients and clinicians tracking new options in blood cancers.

Why it matters

Advanced B-cell lymphomas often return after standard treatments, so early signals of response in heavily pretreated patients are closely watched by the field. These are early, small-group results from a dose-finding study, and they indicate whether IKS03 is worth testing further rather than whether it is ready for use.

This is a preliminary phase 1, multicentre, first-in-human study using a 3+3 dose-escalation design, with 21 patients treated across five dose levels up to 3.1 mg/m2 as of July 8, 2026. Of 17 patients evaluable for efficacy, nine responded (53%), though the trial is still enrolling and results are not yet peer reviewed.

The players

Iksuda Therapeutics

A biopharmaceutical company developing antibody drug conjugates for cancer, including the investigational agent IKS03.

American Society of Haematology

A professional society of blood specialists that hosts an annual meeting where major hematology research is presented.

The details

IKS03 is a CD19-targeting antibody drug conjugate, meaning an antibody guides the drug to cells carrying the CD19 marker found on many B-cell lymphomas. The attached payload is a tumour-activated prodrug pyrrolobenzodiazepine, designed to become active in the tumour environment, which is intended to concentrate its effect on cancer cells. Dose escalation is still underway, and the maximum tolerated dose has not yet been identified.

Timeline

  1. July 8, 2026: data cutoff for treated patient counts and dosing

  2. December 12 to 15, 2026: updated results presented at the 68th ASH Annual Meeting in New Orleans

Health Landscape

CD19-directed antibody drug conjugates such as loncastuximab tesirine have already reached clinical use for relapsed large B-cell lymphoma, establishing the approach. IKS03 adds a tumour-activated payload design and is being evaluated in a wider set of B-cell non-Hodgkin lymphomas.

If you or someone you know has a B-cell lymphoma that has returned after standard treatment, this early research is worth discussing with your oncologist, who can judge whether a clinical trial could be appropriate. For most readers, this is a sign of ongoing research rather than a change in current care.

The takeaway

Early data suggest IKS03 can produce responses in advanced B-cell lymphoma, but the study is small, early, and still testing safety at higher doses. Anyone considering a trial should ask their oncologist about eligibility and what the study would involve.

What happens next

Updated IKS03 phase 1 results are scheduled for presentation at the 68th ASH Annual Meeting in New Orleans, December 12 to 15, 2026.

Further reading

For background on how these therapies are studied and approved, see our Cancer coverage.

More information

Details are listed in the IKS03 phase 1 clinical trial registration.

Source note: This article includes information reported by Pharmabiz.